Do you want to read an article? Please log in or register.
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer
Breast Cancer
Related content
Breast Cancer
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
Ann Oncol
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D
doi: 10.1016/j.annonc.2024.10.015
Gynecologic Cancer
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
Eur J Cancer
Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Maćkowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS
doi: 10.1016/j.ejca.2024.115146
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Jin X, Chen C, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S, Ding L, Zhang L, Ji D, Shen Z
doi: 10.1016/j.lungcan.2024.107901
Genitourinary Cancer
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Eur Urol
Grimm MO, Smith M, Hussain M, Saad F, Fizazi K, Littleton N, Paracha N, Srinivasan S, Verholen F, Tombal B
doi: 10.1016/j.eururo.2025.05.037
Breast Cancer
Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis
Adv Ther
Earla JR, Kurian AW, Kponee-Shovein K, Mahendran M, Song Y, Hua Q, Hilts A, Sun Y, Hirshfield KM, Robson M, Mejia JA
doi: 10.1007/s12325-024-03074-7
Breast Cancer
Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials
Int J Cancer
Menz BD, Modi ND, Abuhelwa AY, Kuderer NM, Lyman GH, Swain SM, Kichenadasse G, Shahnam A, Haseloff M, Vitry A, Rammant E, Ramsey I, Chan RJ, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM
doi: 10.1002/ijc.70020
COMMENTED
Gynecologic Cancer
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
★ 0
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A
doi: 10.1016/j.annonc.2024.08.2241
Multiple Myeloma (MM)
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
Lancet Haematol
Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P
doi: 10.1016/S2352-3026(24)00148-0
Breast Cancer
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
Lancet Oncol
Saito M, Iihara H, Shimokawa M, Udagawa R, Tsuneizumi M, Futamura M, Ishikawa Y, Ogata H, Bando H, Shima H, Hosoya K, Mukohara T, Tanaka K, Ikuta T, Kawate T, Ishida K, Nakai K, Uomori T, Kutomi G, Ozeki R, Yanagisawa N
doi: 10.1016/S1470-2045(25)00233-5